• Trinity Biotech plc (NASDAQ:TRIB) is set to undergo a reverse stock split to potentially stabilize its stock price and attract institutional investors.
• The company received regulatory approval for offshore and outsourced manufacturing of its TrinScreen™ HIV test, aiming to enhance gross margins and scalability.
• Currently, TRIB's stock price has seen significant volatility, with a 27.01% increase in value, indicating a potential turnaround in its financial performance.

Trinity Biotech plc, trading on NASDAQ under the symbol TRIB, is set to undergo a reverse stock split on August 27, 2025. This means for every 5 shares currently held, shareholders will receive 1 new share. The company specializes in diagnostic products, with a focus on its flagship TrinScreen™ HIV rapid test.

Recently, Trinity Biotech received regulatory approval to begin offshore and outsourced manufacturing of its TrinScreen™ HIV test. This strategic shift is expected to enhance the company's gross margins and scalability. By reducing fixed costs, Trinity Biotech aims to support its profitability and growth objectives, ensuring product integrity and regulatory compliance.

Currently, TRIB is priced at $1.74, reflecting a 27.01% increase, or $0.37, in value. The stock has fluctuated between $1.58 and $1.97 today. Over the past year, TRIB has seen a high of $3.44 and a low of $0.48, indicating significant volatility in its stock price.

Trinity Biotech's market capitalization is approximately $18.07 million, with a trading volume of 41.27 million shares. The reverse stock split is a strategic move to potentially stabilize the stock price and attract more institutional investors, aligning with the company's broader financial goals.